News Search Results
Jan 23, 2026, 08:30 ET Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
60 to 200 molecules synthesized and tested in each program.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jan 22, 2026, 23:40 ET 晶泰科技賦能萊芒生物取得細胞療法重大成果，以1‰劑量CAR-T實現多位系統性紅斑狼瘡完全緩解出院
Ltd）是一家處於臨床階段的免疫代謝創新藥物研發公司，由瑞士洛桑聯邦理工學院（EPFL）唐力教授團隊聯合晶泰科技共同創立。基於免疫代謝重編程（META 10）+前沿人工智能（AI）的創新技術，公司專注於研發代謝增強型腫瘤免疫治療藥物。公司核心技術META 10展示出治癒實體腫瘤的巨大潛力，相關成果發表於 Nature、Nature Biotechnology、Nature Immunology、Lancet Haematology 等國際頂級學術期刊，並申請了多項 PCT 專利和中國發明專利。目前公司發展迅速，70% 高層次研發人員來自國內外名校並具有豐富的產業化經驗，多條研發管線進展順利。其中代謝增強型 CAR-T 細胞治療正在開展
More news about: 晶泰科技
Jan 22, 2026, 10:45 ET Medical Electrodes Market Surges to USD 5.2 Billion by 2033, Propelled by 5.5% CAGR - Verified Market Reports®
Global Laboratory Information Management System/LIMS Market Size By Deployment Type (On Premise, Cloud Based), By End User (Pharmaceuticals, Biotechnology), By Software Type (Sample Management, Data Management), By Application (Clinical Research, Quality Assurance), By Distribution Channel (Direct Sales,
More news about: Verified Market Reports
Jan 22, 2026, 10:30 ET Next-Generation Sequencing Market worth $29.53 billion by 2030 | MarketsandMarkets™
sequencing market in 2024.The next-generation sequencing market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, clinical and diagnostic laboratories, and other end users. Academic and research institutes held the largest share of the next-generation
More news about: MarketsandMarkets
Jan 22, 2026, 09:37 ET Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
wet-lab validation through Insilico's automated assay platforms.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jan 22, 2026, 09:11 ET COGNIZIN® CITICOLINE NAMED "FUNCTIONAL INGREDIENT TO WATCH IN 2026" BY MINTEL & BLACK SWAN DATA, SHOWCASING ITS EXPLOSIVE GROWTH IN THE BRAIN HEALTH CATEGORY
— Cognizin® —About Kyowa Hakko USAKyowa Hakko USA is a subsidiary of Kyowa Hakko Bio Co., Ltd., a global biotechnology company with over 75 years of expertise in fermentation, purification, and modification of bioactive substances. Kyowa Hakko Bio is dedicated to
More news about: Kyowa Hakko U.S.A
Jan 22, 2026, 09:00 ET Global Biopharma Company Triples Research Commitment to Tishman Speyer and Breakthrough Properties' One Milestone at the Harvard Enterprise Research Campus, One of Boston's Most Anticipated New Developments
around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies
More news about: Breakthrough Properties
Jan 22, 2026, 07:00 ET PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader
while maintaining favorable safety and combinability profiles.About PAQ TherapeuticsPAQ Therapeutics is a clinical-stage biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options.
More news about: PAQ Therapeutics
Jan 22, 2026, 06:00 ET PhotonPharma Inc. Appoints Vaccine Innovation Leader William Warren, Ph.D. to Board of Directors
the appointment of William Warren, Ph.D., to its Board of Directors, effective immediately. Dr. Warren brings over three decades of experience in biotechnology innovation, vaccine development, and successful entrepreneurship to guide PhotonPharma's strategic initiatives and growth trajectory.
More news about: PhotonPharma Inc.
Jan 22, 2026, 05:00 ET New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
months.7,8NERLYNX is being made available in Thailand by independent pharmaceutical company, Specialised Therapeutics (ST), under exclusive license from Puma Biotechnology, Inc. (Nasdaq: PBYI).ST Chief Executive Officer, Mr Carlo Montagner, said NERLYNX is the first therapy the company is launching in Thailand
More news about: Specialised Therapeutics
Jan 21, 2026, 18:00 ET BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
driving continued growth and improving patient lives and outcomes."About BioTissue Holdings, Inc. BioTissue® is an emerging biotechnology company and leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, specializing in acute and chronic
More news about: BioTissue Holdings, Inc.
Jan 21, 2026, 10:00 ET Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jan 21, 2026, 09:17 ET Doseology Begins Pilot Production of Caffeine-Based Energy Pouches as Feed That Brain® Enters Oral Stimulant Format
VU70) ("Doseology" or the "Company") a leader in biotechnology-driven consumer products, today announced the initiation of a pilot production run of non-nicotine, caffeine-based energy pouches under its wholly
More news about: Doseology Sciences Inc.
Jan 21, 2026, 09:05 ET Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Dr. Quay earned this recognition for his leadership in advancing innovative biotechnology solutions and building a high-performing, people-centered organization. As a physician-scientist and entrepreneur, he has guided the development
More news about: Atossa Therapeutics Inc
Jan 21, 2026, 09:05 ET ISPE Announces Radiopharmaceuticals Community of Practice
share knowledge to accelerate the growth of the industry. The CoP will also work synergistically with other ISPE CoPs, such as those focusing on biotechnology, containment, critical utilities, disposables/single-use technologies, sterile products processing, oral solid dosage, sustainability, HVAC, and
More news about: ISPE
Jan 21, 2026, 08:39 ET DIA Launches ASCENT Platform and LIFT Biotech & Startup Program to Accelerate Emerging Innovation
DIA ASCENT, a new global platform designed to support early-stage biotechnology drug development innovation, along with its inaugural initiative, the
More news about: Drug Information Association
Jan 21, 2026, 08:39 ET DIA Launches ASCENT Platform and LIFT Biotech & Startup Program to Accelerate Emerging Innovation
DIA ASCENT, a new global platform designed to support early-stage biotechnology drug development innovation, along with its inaugural initiative, the
More news about: Drug Information Association
Jan 21, 2026, 08:30 ET NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has
More news about: NeuroSense
Jan 21, 2026, 08:00 ET Pangea Laboratory and Gene Solutions Establish Strategic Collaboration to Advance Cancer Diagnostics in the United States
Gene Solutions, a global biotechnology company, to validate AI-driven liquid biopsy assays for use in cancer detection, characterization, and monitoring within CLIA/CAP laboratory settings
More news about: Pangea Laboratory
Jan 21, 2026, 08:00 ET Variant Bio Appoints Craig T. Basson, MD, PhD, to Advance Genomics-Driven Clinical Programs
President of R&D. Dr. Basson brings more than 25 years of leadership experience across academic medicine, global pharmaceutical development, and biotechnology, with deep expertise in cardiovascular and metabolic disease, human genetics, and translational science.
More news about: Variant Bio
Jan 21, 2026, 07:00 ET L-Nutra Secures $36.5M Investment from Mubadala, Raising Series D Proceeds to $83.5M and Accelerating Global Expansion of Its Longevity and Medical Nutrition Therapies
Ali Abdulla, Executive Director of UAE Clusters, at Mubadala's UAE Investment Platform. "In addition to Mubadala Bio, our biomanufacturing and biotechnology national champion, we continue to execute Mubadala's life sciences strategy by investing in innovative solutions that advance human health and longevity.
More news about: L-Nutra Inc.
Jan 21, 2026, 06:44 ET Veterinary Diagnostics Market to Expand at 10.75% CAGR by 2035 | Discover Strategic Opportunities with Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Jan 21, 2026, 03:00 ET Infinitopes Expands Seed Financing to $35 Million to Accelerate Clinical Development of Precision Cancer Vaccine
OXFORD, England, Jan. 21, 2026 /PRNewswire/ -- Infinitopes, a clinical-stage cancer vaccine biotechnology company, today announced the successful completion of the second close of its seed financing round, securing an additional $15.4 million and bringing
More news about: Infinitopes
Jan 20, 2026, 19:15 ET Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
CAMBRIDGE, Mass., Jan. 20, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and Hygtia Therapeutics Co., Ltd., (Hygtia Therapeutics), today announced a co-development
More news about: Insilico Medicine
Jan 20, 2026, 19:00 ET Rakuten Medical Expands Academic Access to IR700 Dye Through Fee-Only Provision, Greater Publication Freedom and Expanded IP & Commercialization Opportunities
discoveriesSAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox® platform-based photoimmunotherapy, today announced that it will provide IRDye® 700DX N-hydroxy
More news about: Rakuten Medical, Inc.